北京大学学报（医学版）2013，Vol.45Issue(3)：417-421,5.DOI:10.3969/j.issn.1671-167X.2013.03.015
铁饱和重组人乳铁蛋白对大鼠缺铁性贫血的恢复作用
Efficacy of iron saturated recombinant human lactoferrin on alleviating iron deficiency anemia in rats
摘要
Abstract
Objective:To investigate the effect of iron saturated recombinant human lactoferrin (Fe-rhLf) on treating iron deficiency anemia (IDA).Methods:SD rats received iron deficient diet and deionized water during the whole experiment.After 4 weeks,the rats with hemoglobin less than 100 g/L were selected and divided into 5 groups randomly.IDA group received 100 mg/(kg · d) casein dissolved in deionized water intragastrically ; FeSO4 group received 5.43 mg/(kg · d) [2.0 mg/(kg · d) iron] +100 mg/(kg · d) casein intragastrically; low dose Fe-rhLf group received 75.53 mg/(kg · d) Fe-rhLf [0.5 mg/(kg · d) iron] + 75 mg/(kg · d) casein intragastrically ; middle dose group received 151.06 mg/(kg· d) Fe-rhLf [1.0 mg/(kg · d) iron] +50 mg/(kg · d) casein intragastrically; high dose group received 302.11 mg/(kg · d) Fe-rhLf [2.0 mg/(kg · d) iron] intragastrically.After 30 days of intervention,the rats' blood was collected and used to do the routine blood test,serum iron and serum anti-oxidants test.The liver hepcidin and ferroportin mRNA expression was tested by real time PCR.Results:Compared with the animals in the IDA group,Fe-rhLf could increase weight significantly (P ＜0.05),hematological parameters,like hemoglobin (P ＜0.01) and red blood cell count (P ＜0.01) re-covered significantly.Compared with animals in FeSO4 group,high dose Fe-rhLf could improve hemoglobin significantly (P ＜0.05).The liver hepcidin expression was up regulated and ferroportin down regulated.Conclusion:Fe-rhLf has a significant effect on treating iron deficiency anemia.关键词
贫血,缺铁性/乳铁蛋白/重组蛋白质类/硫酸亚铁Key words
Anemia, iron-deficiency / Lactoferrin / Recombinant proteins / Ferrous sulfate分类
医药卫生引用本文复制引用
房玥晖,冯鑫,徐昊,吴峥昊,许雅君..铁饱和重组人乳铁蛋白对大鼠缺铁性贫血的恢复作用[J].北京大学学报（医学版）,2013,45(3):417-421,5.基金项目
卫生部部属(管)医院临床学科重点项目([2007]353-46)和首都医学发展基金(2007-1006)资助Supported by Clinical Research Fund,Ministry of Health of China([2007]353-46) and Capital Medical Development Fund (2007-1006) （管）
